CDH1 Antibody

What is CDH1 and why is it significant in research?

CDH1 encodes cadherin-1 (also known as E-cadherin), a calcium-dependent cell adhesion protein primarily expressed in epithelial tissues. It plays crucial roles in regulating cell-cell adhesions, mobility, and proliferation of epithelial cells . CDH1 is particularly significant in cancer research because it functions as a potent invasion suppressor. At the molecular level, CDH1 promotes organization of radial actin fiber structure and cellular response to contractile forces by facilitating the anchoring of actin fibers to junction complexes at the cell membrane . This protein is extensively studied in cancer biology because mutations in the CDH1 gene are associated with several cancer types, particularly gastric cancer and lobular breast cancer .

What are the common applications for CDH1 antibodies in research?

CDH1 antibodies are versatile tools employed across multiple experimental applications:

• Immunocytochemistry (ICC): For visualizing CDH1 localization at cell-cell junctions in cultured cells

• Western blotting (WB): For detecting and quantifying CDH1 protein expression levels

• Immunohistochemistry (IHC-P): For examining CDH1 expression patterns in paraffin-embedded tissue sections

These applications are essential for investigating epithelial cell biology, epithelial-to-mesenchymal transition (EMT), and cancer progression. The choice of application depends on the specific research question, with ICC providing spatial information about protein localization, WB offering quantitative protein expression data, and IHC revealing tissue distribution patterns.

How do I select the appropriate CDH1 antibody for my specific research application?

Selecting the appropriate CDH1 antibody requires consideration of several factors:

• Specificity verification: Review published validation data and citations to ensure the antibody specifically recognizes CDH1 without cross-reactivity to other cadherins. Some antibodies, like 23C6, demonstrate dual specificity for both CDH1 and CDH11, which may be advantageous or disadvantageous depending on your research question .

• Application compatibility: Confirm the antibody has been validated for your specific application (WB, IHC, ICC). For example, mouse monoclonal E-cadherin antibody (CDH1/1525) has been validated for ICC, WB, and IHC-P applications with human samples .

• Species reactivity: Verify the antibody recognizes CDH1 in your species of interest. Some antibodies recognize both human and murine CDH1, while others are species-specific .

• Epitope location: Consider whether the antibody targets the extracellular domain (useful for functional studies) or intracellular domain (often more stable for detection purposes) of CDH1.

What are the optimal conditions for using CDH1 antibodies in Western blotting?

Successful Western blotting with CDH1 antibodies requires careful optimization:

• Sample preparation: CDH1 is a membrane protein (97.5 kDa) that requires appropriate lysis conditions. Use RIPA buffer supplemented with protease inhibitors, and avoid excessive heating which may cause protein aggregation .

• Gel percentage: Use 7-8% polyacrylamide gels for optimal resolution of the 97.5 kDa CDH1 protein.

• Transfer conditions: Employ wet transfer methods with methanol-containing buffers to effectively transfer this high molecular weight protein.

• Blocking and antibody dilution: 5% non-fat milk in TBST is typically effective for blocking. Antibody dilutions vary by product but generally range from 1:500 to 1:2000 for primary antibodies.

• Controls: Include positive controls (epithelial cell lines known to express CDH1) and negative controls (cell lines with confirmed absence of CDH1 expression or CDH1 knockdown cells) .

How can I optimize immunohistochemistry protocols for detecting CDH1 in tissue samples?

Optimizing IHC for CDH1 detection requires attention to several critical parameters:

• Antigen retrieval: Heat-induced epitope retrieval using citrate buffer (pH 6.0) is typically effective for CDH1 detection in FFPE tissues.

• Antibody concentration: Titrate the antibody to determine optimal concentration. For most commercial CDH1 antibodies, dilutions between 1:100 and 1:500 are appropriate starting points.

• Incubation conditions: Overnight incubation at 4°C often yields superior staining compared to shorter incubations at room temperature.

• Detection system: Use sensitive detection systems like polymer-based methods for best results. The membranous staining pattern of CDH1 should be carefully evaluated for specificity.

• Positive and negative controls: Include normal epithelial tissues as positive controls and stromal regions as internal negative controls. CDH1-negative lobular breast carcinomas can serve as valuable negative control tissues .

What are the best practices for interpreting CDH1 immunostaining patterns in cancer tissues?

Interpreting CDH1 immunostaining requires understanding normal expression patterns and recognizing abnormal patterns associated with pathological conditions:

• Normal pattern: Strong, continuous membranous staining at cell-cell contacts in epithelial tissues.

• Reduced membranous expression: Often observed in carcinomas undergoing EMT, indicating potential invasive properties.

• Cytoplasmic localization: May indicate internalization and degradation of CDH1, frequently associated with E-cadherin dysfunction.

• Complete loss of expression: Common in lobular breast carcinomas and diffuse-type gastric cancers, often associated with CDH1 mutations .

• Heterogeneous expression: May reflect tumor heterogeneity or partial EMT states, requiring careful documentation of staining patterns across the entire tissue section.

How do CDH1 mutations affect antibody binding and detection?

CDH1 mutations can significantly impact antibody detection in several ways:

• Truncating mutations: Premature stop codons or frameshift mutations may result in truncated proteins that lack the epitope recognized by certain antibodies. This is particularly relevant for antibodies targeting the C-terminal region of CDH1.

• Missense mutations: These may alter protein conformation or epitope structure, potentially reducing antibody affinity or completely preventing binding.

• Domain-specific impacts: Mutations in specific domains may selectively affect antibodies targeting those regions while antibodies recognizing other domains remain effective.

• Complete protein loss: In some cases, mutations lead to complete absence of protein expression, resulting in negative staining with all CDH1 antibodies .

For accurate interpretation, researchers should understand their antibody's target epitope and consider using multiple antibodies targeting different CDH1 domains when studying samples with known or suspected CDH1 mutations.

What is the relationship between CDH1 mutations and cancer progression?

CDH1 mutations play significant roles in cancer development and progression:

• Gastric cancer: CDH1 mutations are characteristic of genomically stable gastric cancer subtypes. In a large-scale analysis, CDH1 mutation frequency was 9.7% in gastric cancer patients . These mutations are particularly associated with hereditary diffuse gastric cancer (HDGC) .

• Molecular associations: CDH1-mutated gastric cancers show distinctive molecular patterns:

  • Higher mutation rates in ARID1A, WRN, POT1, CDK12, and FANCC genes

  • Lower mutation rates in TP53 and APC genes

  • Lower rates of KRAS and HER2 amplifications

  • Higher rates of CRKL and IGF1R amplifications

• Immunotherapy implications: CDH1-mutated gastric cancers demonstrate significantly lower rates of PD-L1 positivity (56.7% vs. 73.3% in CDH1 wild-type), suggesting potential reduced benefit from immunotherapy approaches .

• Breast cancer: CDH1 mutations are associated with lobular breast cancer, which typically shows complete loss of E-cadherin expression .

• Metastatic potential: Loss of CDH1 function is linked to increased metastatic potential in multiple cancer types, particularly through mechanisms involving epithelial-to-mesenchymal transition .

How can dual-specificity cadherin antibodies be utilized in metastasis research?

Novel dual-specificity antibodies targeting both epithelial E-cadherin (CDH1) and mesenchymal OB-cadherin (CDH11) represent an innovative approach in metastasis research:

• Addressing tumor heterogeneity: Dual cadherin antibodies can recognize both epithelial and mesenchymal phenotypes, addressing the challenge of tumor cell heterogeneity and dynamic cadherin expression during EMT .

• Targeting circulating tumor cells (CTCs): Studies demonstrate that dual cadherin antibodies like 23C6 can reduce CTCs in blood without obvious toxicity to normal tissues in breast and pancreatic cancer mouse models .

• Therapeutic potential: These antibodies show anti-metastatic activity in various cancer models, suggesting potential applications in perioperative and oligometastatic settings to prevent further tumor cell dissemination .

• ADC development: Conjugation of dual cadherin antibodies with cytotoxic drugs (antibody-drug conjugates) can enhance their cytotoxicity. For example, 23C6 antibody has been successfully conjugated to SN-38, the active metabolite of irinotecan .

• Binding mechanism: Structural analysis of dual-specificity antibodies reveals conserved binding regions between CDH1 and CDH11, with 58.5% amino acid homology in potential binding site 1 and 42.9% in potential binding site 2 .

What are the latest approaches for using CDH1 antibodies in studying epithelial-to-mesenchymal transition (EMT)?

EMT research utilizing CDH1 antibodies has evolved to include sophisticated approaches:

• Live-cell imaging: Using fluorescently-tagged CDH1 antibodies to monitor real-time changes in E-cadherin localization and expression during EMT induction.

• Multiplexed immunostaining: Combining CDH1 antibodies with markers of mesenchymal transition (N-cadherin, vimentin) and EMT transcription factors (Snail, Twist, ZEB1/2) to comprehensively characterize EMT states.

• Single-cell analysis: Employing CDH1 antibodies in flow cytometry or mass cytometry (CyTOF) for phenotypic characterization of heterogeneous cell populations undergoing partial or complete EMT.

• Dual cadherin targeting: Utilizing dual-specificity antibodies that recognize both epithelial (CDH1) and mesenchymal (CDH11) cadherins to track cells through various EMT states .

• Functional blocking studies: Using CDH1 function-blocking antibodies to investigate the direct role of E-cadherin in maintaining epithelial integrity and preventing EMT.

How can CDH1 antibodies be used to study the roles of E-cadherin in cell adhesion complex formation?

CDH1 antibodies provide valuable tools for investigating E-cadherin's role in adhesion complexes:

• Co-immunoprecipitation: Using CDH1 antibodies to pull down E-cadherin complexes to identify interaction partners, including catenins (α, β, p120) and other components of adherens junctions.

• Proximity ligation assays: Combining CDH1 antibodies with antibodies against potential interaction partners to detect and visualize protein-protein interactions at the single-molecule level.

• Super-resolution microscopy: Employing CDH1 antibodies in techniques like STORM or PALM to visualize nanoscale organization of adherens junctions, revealing insights into how E-cadherin promotes organization of radial actin fiber structures .

• FRET/FLIM analysis: Using fluorescently-labeled CDH1 antibodies in Förster resonance energy transfer or fluorescence lifetime imaging microscopy to study dynamic protein interactions within adhesion complexes.

• In vitro reconstitution: Combining purified E-cadherin with its binding partners to reconstitute minimal adhesion complexes in vitro, using CDH1 antibodies to validate complex formation.

How can I address non-specific binding issues with CDH1 antibodies?

Non-specific binding is a common challenge when working with CDH1 antibodies:

• Antibody validation: Verify antibody specificity using positive controls (epithelial cell lines) and negative controls (CDH1 knockdown cells, as demonstrated with shCDH11 knockdown cells in MDA-MB-231 cells) .

• Blocking optimization: Test different blocking agents (BSA, normal serum, commercial blocking solutions) and concentrations to minimize background.

• Antibody concentration: Titrate antibody concentrations to find the optimal balance between specific signal and background.

• Cross-reactivity considerations: Be aware that some CDH1 antibodies may cross-react with other cadherin family members due to sequence homology. For example, the 23C6 antibody shows strong reactivity with both CDH11 and CDH1, with lesser reactivity to CDH2 .

• Secondary antibody controls: Include controls omitting primary antibody to identify potential secondary antibody non-specific binding.

What strategies can I employ when CDH1 antibodies fail to detect expected signals in my samples?

When facing detection challenges with CDH1 antibodies, consider these troubleshooting strategies:

• Epitope accessibility: CDH1 is calcium-dependent, and calcium depletion can alter conformation and epitope accessibility. Ensure buffers contain appropriate calcium concentrations.

• Protein degradation: CDH1 can undergo proteolytic processing. Use fresh samples and include protease inhibitors during sample preparation.

• Alternative antibodies: Try antibodies recognizing different epitopes, as mutations or processing may affect specific regions of the protein.

• Sample preparation: Optimize fixation conditions for ICC/IHC, as overfixation can mask epitopes. For Western blotting, adjust lysis conditions to effectively solubilize this membrane protein.

• Expression verification: Confirm CDH1 expression at the mRNA level using RT-PCR or RNA-seq, as some samples may have downregulated or lost CDH1 expression, particularly in cancer contexts .

How can I accurately interpret changes in CDH1 expression patterns in the context of cancer progression?

Interpreting CDH1 expression patterns in cancer requires nuanced analysis:

What considerations are important when comparing CDH1 antibody results across different experimental systems?

When comparing CDH1 antibody results across different experimental systems:

• Antibody consistency: Ideally use the same antibody clone across experiments, as different antibodies may recognize distinct epitopes with varying affinities.

• Protocol standardization: Standardize sample preparation, antibody concentration, and detection methods to enable meaningful comparisons.

• Positive controls: Include consistent positive controls across experiments to normalize for technical variations.

• Quantification methods: Use consistent quantification methods, whether analyzing band intensity in Western blots or staining intensity in immunohistochemistry.

• Biological context differences: Consider inherent differences between in vitro cell lines, animal models, and human samples when interpreting CDH1 expression patterns. Gene set enrichment analysis of CDH1-mutated versus wild-type samples reveals significant differences in pathways including EMT, inflammatory responses, apical junction formation, and DNA repair mechanisms .